Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 5-Year Average (2.8), the stock would be worth $0.02 (100% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 583.7 | $9.78 |
0%
|
| 5-Year Average | 2.8 | $0.02 |
-100%
|
| Industry Average | 21.8 | $0.13 |
-99%
|
| Country Average | 21.9 | $0.14 |
-99%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
B
|
Bioventus Inc
NASDAQ:BVS
|
804.1m USD | 1 583.7 | 35.6 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 51 | 39.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.2B CHF | 26.2 | 36.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
89.7B DKK | 17.7 | 22.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 25.6 | 30.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -119.2 | -37.9 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.7 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 33.8 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | 10.5 | 22.2 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
875B JPY | 23.5 | 49.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
